#Opioid Market

[industryforecastnews]

Opioid Market Size, Share, Trends And Industry Outlook Report, 2030

Opioids Market Growth & Trends

The global opioid market size is expected to reach USD 25.3 billion by 2030, registering a CAGR of 1.4% during the forecast period, according to a new report by Grand View Research, Inc. Supportive regulatory policies aid manufacturers to introduce products that may contribute to the market growth. For instance, in June 2021, the U.S. FDA approved nalmefene hydrochloride injection developed by Purdue Pharma L.P.Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose. The expected approval of a product is anticipated to drive the growth. 

Moreover, in June 2021, morphine sulfate tablets and morphine sulfate oral solution were approved by FDA for the management of severe pain in pediatric and adult patients for whom other treatment options were less. Thus, approval of new opioid and their launch is also expected to drive the growth. 

Growing use of the opioids for the management of post-operative pain, caused due to the surgeries, is expected to drive the market growth. According to the Canadian Centre on Substance Use and Addiction, in 2020, approximately 11.8% of all the population used opioid analgesics for the management of symptoms. Tramadol and codeine are frequently dispensed for the postoperative opioid prescription in surgeries within the region. 

Emergence of non-addictive alternative products to opioids for the pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets. 

In addition, in February 2022, the U.S. FDA has undertaken an initiative to encourage the development of non-addictive analgesics alternatives to opioids under its HHS overdose prevention strategy for the management of acute and chronic pain. The regulatory agency issued recommendation to pharmaceutical companies to develop non-opioid analgesic products. Such initiatives may restrain the overall growth of the opioids market. 

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/opioids-market

Opioids Market Report Highlights

By product, ER/long acting opioids segment held the largest market share in 2022 due to the increasing approval and launch of the novel ER/ long-acting opioids. For instance, in June 2021, the U.S. FDA accepted a review application for a new drug application for buprenorphine (Brixadi) for the pain management. Buprenorphine is an extended release long-acting opioid drug

By application, pain relief segment dominated the opioids market in 2022 and is expected to witness significant market growth owing to increasing prevalence of the patients with chronic pain. According to the Canadian Institute for Health Information and Canadian Pain Task Force report of 2021, 1 in every 5 adults in Canada suffers from chronic pain

By route of administration, injectable segment dominated the opioids market in 2022. This dominance can be attributed to wide availability of products used for the treatment of chronic pain and increased procedures requiring anesthesia

By distribution channel, retail pharmacy dominated the opioids market in 2022. The availability of retail pharmacies with high dispensing rate of opioid driving segment growth

Asia pacific is expected to be the fastest growing region during the forecast period. The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain. 

Opioids Market Segmentation

Grand View Research has segmented the global opioid market based on product, application, route of administration, distribution channel, and region:

Opioids Product Outlook (Revenue, USD Million, 2018 - 2030)

IR/Short Acting Opioids

ER/Long-Acting Opioids

Opioids Application Outlook (Revenue, USD Million, 2018 - 2030)

Pain relief

Anesthesia

Cough suppression

Diarrhea suppression

De-addiction

Opioids Route of administration Outlook (Revenue, USD Million, 2018 - 2030)

Oral

Injectable

Others

Opioids Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospital pharmacy

Retail Pharmacy

Others

Opioids Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

List of Key Players in the Opioids Market

Purdue Pharma L.P.

Johnson & Johnson Services, Inc.

Hikma Pharmaceuticals PLC

Pfizer, Inc.

AbbVie Inc.

Sanofi

Sun Pharmaceutical Industries Ltd

Grünenthal

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/opioids-market

[one-winged-dreams]

I'm definitely going to have to add Wedge as a platonic after that dream I just had.

[health-views-updates]

Future Trends in the Opioid Use Disorder Market: Size, Share, and Demand

The Opioid Use Disorder Market Revenue was valued at USD 3.40 billion in 2023 and is expected to grow significantly, reaching USD 6.97 billion by 2031. This growth, at a CAGR of 9.4% over the forecast period of 2024-2031, underscores the increasing prevalence of opioid use disorder and the urgent need for innovative treatment options to combat this global health crisis.

Key Market Drivers

The rising prevalence of opioid addiction, coupled with the increasing awareness about opioid use disorder and its treatment options, is driving market growth. Governments and healthcare organizations are investing heavily in research and development initiatives to address the opioid epidemic, thereby fueling demand for advanced therapeutic solutions.

Advancements in treatment modalities, including medication-assisted therapies (MAT) and behavioral counseling, have played a pivotal role in improving recovery outcomes. Medications such as buprenorphine, methadone, and naltrexone are widely prescribed to help manage withdrawal symptoms and reduce the risk of relapse. Moreover, the integration of digital therapeutics and telemedicine services is enhancing patient access to care, especially in underserved regions.

Regional Insights

North America dominates the opioid use disorder market due to the region’s high prevalence of opioid misuse and favorable government policies supporting treatment programs. Europe and Asia-Pacific are also witnessing significant growth, driven by increasing healthcare expenditures, expanding awareness campaigns, and the rising adoption of evidence-based treatments.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/3018

Market Outlook

With the opioid crisis showing no signs of abating, the demand for comprehensive treatment solutions is expected to remain high. The introduction of novel pharmacological treatments, coupled with supportive government initiatives, will be instrumental in shaping the future of the market. As public and private sector investments in research and development grow, the opioid use disorder market is poised for sustained expansion.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[marketsndata]

[soumyafwr]

Non-opioid Pain Treatment Market Size, Overview, Share and Forecast 2031

[blog-site-for-market-research]

Opioids Market Global Industry Analysis and Forecast (2023-2032)

Market Overview ��

The opioids market is predicted to grow at a 5.4% CAGR between 2023 and 2032, reaching USD 6.93 billion.

The Opioids Market encompasses pharmaceutical drugs derived from opium or synthesized to mimic its effects, primarily used for pain management. Opioids are potent analgesics commonly prescribed for acute and chronic pain conditions, including postoperative pain, cancer-related pain, and severe injuries. However, the widespread use of opioids has led to concerns about addiction, overdose, and misuse.

The opioids market, while grappling with addiction concerns, sees a promising trend with the growing adoption of naltrexone. This medication offers a novel approach to managing opioid dependence by blocking opioid receptors, reducing cravings and withdrawal symptoms. As awareness rises, naltrexone's role in addiction treatment strengthens, contributing to a multifaceted approach to opioid management.

In recent years, the opioids market has witnessed significant growth globally due to several factors. Firstly, there has been increasing recognition of the need for effective pain management options, particularly in the context of aging populations and rising prevalence of chronic pain conditions. Key players in this market include pharmaceutical companies, healthcare providers, pain management clinics, and regulatory agencies, collaborating to develop and distribute opioids responsibly while mitigating risks of abuse and addiction.

Moreover, advancements in opioid formulations and delivery systems have led to the development of extended-release, abuse-deterrent, and non-opioid combination products. These innovations aim to improve pain control, reduce side effects, and minimize the potential for addiction and misuse.

Segment analysis

The segment study for the global opioids market is done by product, end-users, and applications. The product based segments of the opioids market are immediate-release/short-acting opioids and extended-release/long-acting opioids. The sub-segments of the extended-release opioid segment are morphine, oxycodone, oxymorphone, and hydromorphone among others. The extended-release opioid segment can value above USD 12,750.91 Mn by 2027. The sub-segments of the immediate-release opioid segment are hydrocodone, codeine, morphine, and fentanyl among others. The application-based segments of the opioids market are anesthesia, pain relief, diarrhoea suppression, cough suppression, and de-addiction. The end-user based segments of the global opioids market are pharmacies, academic research institutes, and hospitals & clinics. The end-user segments can largely benefit the opioids market.

Regional Analysis

The opioids market in Americas can secure the largest share of the worldwide global opioids market in the study period. The increase in the application of intravenous usage of opioids due to its fast action can promote the regional market rise in the near future. The growing awareness of IV application of opioids and its medical uses can drive the regional market in the near future. The market in Americas can accounted for the major share of the worldwide opioids market owing due rise in intravenous drug application. In Europe, the opioids market can thrive owing to the rise in demand for palliative care facilities. The introduction of reformed regulations for prescribing opioids can promote the market in the region. In Asia Pacific, the market is likely to be fast growing through the review period. Populace demographics and rise in availability of effective opioid medicines can favor the Asia Pacific opioids market in the analysis period. In South Korea, the market can secure about 6% of the APAC opioids market by 2027. In the Middle East and Africa region, a steady rise for the market is likely due to increase in count of opioid manufacturers in the region.

Key Players –

Opioids key players include Sanofi from France, Teva Pharmaceutical Industries from Israel, Bristol-Myers Squibb from the US, AbbVie Inc. from the US, Boehringer Ingelheim International GmbH from Germany, Purdue Pharma from the US, Astellas Pharma Inc. from Japan, Pfizer Inc. from the US, Biogen Idec from the US, Bayer from Germany, and GlaxoSmithKline from the UK.

Related Reports –

amniotic membrane market

asia pacific aesthetics market

diabetic nephropathy market

chronic kidney disease market

For more information visit at MarketResearchFuture

[pharmanucleus1]

Global Opioid Use Disorder Market: Navigating the Insights and Innovations

Opioid Use Disorder Market 

KEY MARKET INSIGHTS 

The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder 

Opioid Use condition (OUD) is a complicated condition characterised by the compelling use of opioid medicines, even if the individual wishes to quit or if the drugs significantly impact the person's mental and physical well-being. Buprenorphine, methadone, and naltrexone are the three pharmacological groups used in the pharmaceutical therapy. These are the only drug classes authorised by the FDA in the United States. 

The number of prescriptions for painkillers, which commonly contain opioids, is expected to climb as the worldwide population of individuals suffering from chronic pain grows. When these opioid-based medications are used and the patient's suffering is relieved, the patient's reliance or addiction to these drugs rises. This addiction is dangerous since an opioid overdose can result in death or lifelong impairment of a person's normal psychological and physiological functioning. 

Several governments, like the United States, have put laws in place to successfully handle this condition in order to lessen the risk. These legislative reforms, together with the increasing number of product releases by big corporations, are expected to have a positive influence on the sector. 

Click here for sample request:

https://www.pharmanucleus.com/request-sample/1182

POST COVID-19 IMPACT 

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth? 

Depending on the demand, the COVID-19 pandemic had both beneficial and bad effects on pharmaceutical firms. Certain pharmaceutical items saw a drop in demand as fewer individuals risked visiting healthcare institutions such as hospitals and clinics. To stop the spread of the coronavirus epidemic, the different governments ordered strict national lockdowns. As a consequence, patient visits to hospitals decreased dramatically. Non-essential medical services cancellation or delay impacted market development as well. 

On the other side, there was a noticeable increase in patients having opioid overdoses and relapses in the OUD market. However, well-known firms in the field, such as Indivior, saw a significant drop in product sales during this time. Sales continued to fall sharply as a result of Covid-19-related problems. As a result, the worldwide market saw a negative trend during the epidemic. 

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder

LATEST TRENDS 

Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth 

The industry has lately seen an increase in the demand for buprenorphine treatment patches. These patches are regarded as an effective medication for the treatment of opioid use disorders. The numerous advantages associated with transdermal patches, such as ease of medication delivery and decreased discomfort, are customary and self-administered. Furthermore, these transdermal patches may be a viable option for individuals requiring round-the-clock opioid medication for opioid use disorder. 

In 2019, for example, WellSpan Health collaborated with York Opioid Collaborative to conduct a clinical study to develop a Lidocaine patch for the treatment of OUD. During the projected period, such collaboration is expected to boost treatment uptake. Furthermore, increased patient participation is expected to drive worldwide Opioid Use Disorder (OUD) market growth throughout the forecast period. 

DRIVING FACTORS 

Growing Opioid Addiction Cases to Augment the OUD Market Share? 

The worldwide population is today suffering from a variety of severe and chronic ailments, including pain, cancer, cardiovascular disease, and other problems. To treat these problems, painkillers, particularly opioids, are used. Drug usage frequently leads to drug addiction in the patient. The patient is expected to have drug withdrawal symptoms as a result of their increasing reliance on these drugs and their sudden discontinuation. 

According to the National Drug Dependence Treatment Centre's (NDDTC) Magnitude of Substance Use in India report published in February 2019, the prevalence of current opioid use is 2.06%, and approximately 0.55% of Indians are expected to require help for opioid use problems (harmful use and dependence). 

On account of these factors, the likelihood that patients will experience tragic outcomes, such as death induced by an opioid overdose, rises. 

Growing Focus of Government & Non-government Institutions to Support Expansion 

Another major driving reason driving market development is the growing involvement of governmental and non-governmental organisations in raising awareness about opioid overdose and associated consequences. The number of opioid addicts has substantially grown, prompting various organisations to take a more comprehensive strategy to combating the problem. Numerous countries have increased their efforts to support patients and reduce the effects of opioid addiction. 

For example, in March 2022, the Department of Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and prevent prescription drug misuse. 

Similarly, similar programmes are expected to encourage more people suffering from opioid addiction to seek treatment. These factors are expected to have a positive impact on the worldwide market throughout the forecast period. 

RESTRAINING FACTORS 

Adverse Effects of OUD Drugs to Restrain Market Growth? 

The adverse effects of the medications used to treat opioid addiction are expected to stymie the market throughout the projected period. 

These medicines commonly cause muscular pains, vomiting, diarrhoea, bone/joint pain, respiratory difficulties, bladder discomfort, constipation, and stomach cramps. Furthermore, in severe situations of adverse medication response, the patient may suffer from depression and other psychological issues. 

The hazards connected with these pharmaceuticals have resulted in a warning from the US Food and Drug Administration, which has a negative influence on the drug class, lowering the adoption of medications in this form of treatment. 

For instance, in January 2022, the U.S. FDA warned about dental problems with buprenorphine medicines dissolved in the mouth to treat OUD and pain. Dental issues, including oral infections, cavities, tooth decay, and teeth loss can be serious and have been reported even in patients with no history of dental issues. 

Such factors might hamper the market growth during the forecast period to a certain extent. 

[meghanester]

Opioid Dependence Treatment Market to Expand at a Stunning CAGR of ~9% Assessment | Segments, Expansion, Demand, and Opportunities During 2023-2035

Global Opioid Dependence Treatment Market Key Insights 

During the forecast period of 2023-2035, the global opioid dependence treatment market is expected to reach an estimated value of ~USD 7 billion by 2035, by expanding at a CAGR of ~9%. The market further generated a revenue of ~USD 3 billion in the year 2022. Major key factors propelling the growth of opioid dependence treatment market worldwide are the growing cases of opioid abuse, and addiction of individuals on illegal opioid drugs all across the globe.

Market Definition of Opioid Dependence Treatment

Aspects of opioid dependency and opioid use disorders are combined in opioid dependence. Many different locations and pharmacological and behavioral treatment modalities are employed to treat opioid drug addiction. Most currently being utilized treatments focus on maintenance therapy using buprenorphine, an opioid agonist, together with methadone, naltrexone, or an opioid antagonist. As a rescue medication in the case of an overdose, buprenorphine is occasionally used with naloxone in rare circumstances.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-4003

Global Opioid Dependence Treatment Market: Growth Drivers 

The growth of the global opioid dependence treatment market can majorly be attributed to the growing consumption of opioid drugs, which could further cause opioid use disorder among people. Opioid use disorder (OUD) has affected 3 million US residents and 16 million other people worldwide. Further, in the United States, about 500,000 people are addicted to heroin. Opioid addiction is a chronic disease that could have serious negative effects on one's health, relationships, and finances. Opioids are a group of medications that work on the neurological system to relieve pain and elicit a sense of euphoria. Hence, growth in the number of people suffering from chronic illnesses is also expected to consume opioid drugs further boosting the growth of the market. For instance, nearly half of all Americans—roughly 45%, or 133 million people—suffer from at least one chronic illness, and the number is rising. However, despite being often used for therapeutic purposes, opioid medicines carry the risk of abuse, dependency, and other health issues if used excessively or without supervision. For instance, according to the World Health Organization, drug use is responsible for 0.5 million fatalities globally. Overdose is the primary cause of nearly 30% of these deaths, which have an opioid connection in excess of 70%. Hence this factor is expected to boost the growth of the market in coming years.

The global opioid dependence treatment market is also estimated to grow majorly on account of the following: 

Growing Government Initiatives to Tackle Opioid Dependence Treatment Effectively

Surge in Consideration of Buprenorphine Patches

Increasing Engagement of Non-Government Organization

Request for customization @ https://www.researchnester.com/customized-reports-4003

Global Opioid Dependence Treatment Market: Restraining Factor 

The side effects that could result from the medications used to treat opioid addiction are one of the most important restraints that are projected to restrict the expansion of the global market over the forecast period. Vomiting, bladder pain, abdominal cramps, diarrhoea, respiratory problems, bone/joint pain, muscular aches, and constipation are just a few of the common side effects from these medications. Additionally, in very severe circumstances of adverse effects, the patient may also experience psychological issues including depression. In some instances, using SUBOXONE to treat opioid dependence might cause hyperventilation and a fast or irregular heartbeat. Thus, it is anticipated that during the projection period, these medications' negative effects would impede market expansion.

Global Opioid Dependence Treatment Market Segmentation 

By Drug Class (Naloxone, Buprenorphine, and Methadone)

The buprenorphine segment is anticipated to hold the largest market share over the forecast period. The growth of this segment could be attributed to the growing usage of buprenorphine for opioid use disorder. Buprenorphine is a medicine licensed by the Food and Drug Administration (FDA) as a medication-assisted treatment (MAT) for Opioid Use Disorder (OUD). However, overdose of buprenorphine could cause adverse effect on health. In the past few years, it has been observed that the misuse of buprenorphine was on the rise, mostly among heroin users. The high opioid abuse in order to treat pain, manage psychiatric disorders, get high, manage withdrawal symptoms, and more, further lead to high consumption of buprenorphine as to wean themselves off opioids. However, prevalence of Buprenorphine abuse among adults with OUD decreased from 2015 to 2019. In 2019, approximately 2.4 million US individuals used buprenorphine, and close to 0.7 million abused it, compared to approximately 4.9 million and about 3.0 million in previous years, respectively, who misused hydrocodone and oxycodone.

By Sales Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Rehabilitation Centers)

By Region

The North America opioid dependence treatment market is anticipated to hold the largest market share by the end of 2035 among the market in all the other regions, backed by rising awareness among general population about opioid use disorder, and growth in patient pool in the region. According to a survey conducted in 2019 by the U.S. Department of Health and Human Services, 10.1 million adults aged 12 and older abused opioids in 2018, compared to 9.7 million adults who misused prescription painkillers.

The market research report on global opioid dependence treatment also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa). 

Key Market Players Featured in the Global Opioid Dependence Treatment Market 

Some of the key players of the global opioid dependence treatment market are Orexo AB, Indivior PLC, Titan Pharmaceuticals, Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, BioDelivery Sciences International Inc., Teva Pharmaceutical Industries Ltd., Alkermes, Camurus AB, and others.

Obtain this Report @ https://www.researchnester.com/reports/opioid-dependence-treatment-market/4003

About Research Nester 

Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. 

Contact for more Info: 

AJ Daniel 

Email: info@researchnester.com 

U.S. Phone: +1 646 586 9123  

U.K. Phone: +44 203 608 5919 

[versatile-blogger-1]

U.S. Opioids Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of Chronic Pain

Market Overview: The U.S. Opioids Market offers a range of pharmaceutical products that are used to manage and treat chronic pain. Opioids are highly effective in relieving moderate to severe pain, making them essential for patients suffering from conditions such as cancer, post-surgical pain, and chronic musculoskeletal pain. The market provides a variety of opioids, including extended-release formulations that provide long-lasting pain relief. The advantages of opioids include their ability to alleviate pain and improve the quality of life for patients with chronic pain conditions. The need for these products is driven by the increasing prevalence of chronic pain across the United States. Market Key Trends: One key trend in the U.S. Opioids Market is the growing adoption of abuse-deterrent formulations. Due to the addictive nature of opioids, there has been a rise in the misuse and abuse of these drugs. To address this issue, pharmaceutical companies have developed abuse-deterrent formulations that make it harder for individuals to manipulate the drug for non-medical purposes, such as crushing or dissolving it. These formulations incorporate physical or chemical barriers that prevent abuse and discourage tampering. The adoption of abuse-deterrent formulations is expected to increase, driven by regulatory initiatives and healthcare provider awareness about the risks associated with opioid misuse. The global U.S. Opioids Market Growth is estimated to be valued at US$16,285.2 million in 2022 and is expected to exhibit a CAGR of 5.5% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. PEST Analysis: Political: The political landscape plays a significant role in the U.S. opioids market. Government regulations and policies addressing drug usage and prescription are crucial factors that impact the market. These regulations aim to control the opioid crisis, reducing the misuse and addiction associated with these drugs. Economic: The economic factors influencing the U.S. opioids market include healthcare expenditure, insurance coverage, and the overall economic condition of the country. Economic growth and stability can contribute to increased healthcare spending, leading to higher demand for opioids. Social: The social aspect of the U.S. opioids market revolves around the societal perception of pain management and the use of opioids. Public awareness campaigns and education regarding addiction and overdose risks have influenced social attitudes towards opioids, leading to increased caution and a decline in opioid prescriptions. Technological: Technological advancements such as pain management devices, drug delivery systems, and digital health solutions are transforming the U.S. opioids market. These innovations enhance the efficacy of pain management while minimizing the risks associated with opioids. Key Takeaways: The U.S. opioids market is expected to witness high growth, exhibiting a CAGR of 5.5% over the forecast period from 2022 to 2030. The market is driven by increasing cases of chronic pain, the aging population, and the growing prevalence of conditions requiring palliative care. Furthermore, the rising awareness about pain management and the introduction of advanced technologies are also contributing to market growth. Regionally, the United States dominates the opioids market due to its well-established healthcare infrastructure, high healthcare expenditure, and the prevalence of chronic pain conditions. The country is at the forefront of developing regulations to control the opioid crisis, leading to a decline in opioid prescriptions and increased focus on alternative pain management approaches.

[cmibloggers]

Global Opioids Agonist Drugs Market Is Estimated To Witness High Growth Owing To Increasing Use of Opioids for Pain Management

The global Opioids Agonist Drugs market is estimated to be valued at US$ 17,132.5 million in 2015 and is expected to exhibit a CAGR of 4.2% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview: Opioids agonist drugs are a class of medications primarily used for pain management. They act on the opioid receptors in the brain and spinal cord to reduce the perception of pain. Opioids are highly effective in managing moderate to severe pain in conditions such as cancer, trauma, and post-surgical pain. The advantage of opioids agonist drugs lies in their ability to provide significant pain relief, improving the quality of life for patients suffering from chronic pain.

B) Market Key Trends: One key trend in the Opioids Agonist Drugs Market is the increasing use of opioids for pain management. Chronic pain affects a significant portion of the global population, and opioids are often the go-to choice for managing such pain. The rise in chronic diseases, such as cancer, arthritis, and neurological disorders, has further fueled the demand for opioids agonist drugs. For example, according to the World Health Organization, it is estimated that over 382 million people globally suffer from diabetes, a condition that often leads to neuropathic pain requiring opioid-based pain management.

C) Pest Analysis: - Political: Governments worldwide have tightened regulations on opioid prescriptions due to concerns over misuse, addiction, and overdose. This has led to stricter control over opioid distribution and increased scrutiny over healthcare providers prescribing opioids. - Economic: The growing incidence of chronic diseases and an aging population have contributed to the increased demand for opioids agonist drugs. Additionally, the economic burden of chronic pain on healthcare systems has prompted investments in effective pain management solutions. - Social: The stigma associated with opioids and the rising awareness about addiction and abuse have led to greater caution among healthcare providers in prescribing opioids. Additionally, there is a growing demand for safer alternatives to opioids for pain management. - Technological: Advancements in drug delivery systems, such as transdermal patches and extended-release formulations, have improved the efficacy and safety profile of opioids agonist drugs. Furthermore, telemedicine and remote patient monitoring technologies have facilitated better pain management for patients in remote areas.

D) Key Takeaways: - Market size: The global opioids agonist drugs market is expected to witness high growth, exhibiting a CAGR of 4.2% over the forecast period, due to increasing use of opioids for pain management. - Regional analysis: North America is the fastest-growing and dominating region in the opioids agonist drugs market, attributed to the higher prevalence of chronic pain conditions and favorable reimbursement policies. - Key players: Key players operating in the global opioids agonist drugs market include Pfizer Inc., Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, and Endo Pharmaceuticals Inc. These companies focus on research and development activities to introduce innovative products and maintain their market position. In conclusion, the global opioids agonist drugs market is expected to witness significant growth in the coming years driven by the increasing use of opioids for pain management. However, strict regulations and the need for safer alternatives present challenges for the market players. Nonetheless, advancements in drug delivery systems and technology offer opportunities for market expansion.

[marketspace360]

Opioids Market Expected to Witness High Growth over the Forecast Period 2022-2029

[soumyafwr]

https://www.cienciared.es/blogs/226416/Non-opioid-Pain-Treatment-Market-Size-Overview-Share-and-Forecast

Non-opioid Pain Treatment Market Size, Overview, Share and Forecast 2031

[reportstores]

KemPharm Drug KP201 Proven to Relieve Pain

A Phase I clinical trial of KP201, KemPharm's Opioid Induced Constipation Drugs Development Market , produced positive results.

24 healthy volunteers participated in the Phase I study, which included a single dose, three treatments, three periods, six sequences, and a crossover. It found that the drug candidate reduced pain and had a better pharmacokinetic profile.

The study also looked at the safety and tolerability of intact KP201 and hydrocodone concentrations in the blood.

The study also looked at the safety and tolerability of intact KP201 and hydrocodone concentrations in the blood.